当前位置: X-MOL 学术Lancet Respir. Med. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Clinical trial research in focus: ensuring new cystic fibrosis drugs fulfil their potential
The Lancet Respiratory Medicine ( IF 38.7 ) Pub Date : 2017-09-01 , DOI: 10.1016/s2213-2600(17)30311-9
J Stuart Elborn , Jane Davies

First page of articleExtraordinary advances have been made in improving the outcome for people with cystic fibrosis over the past 50 years. Children born with cystic fibrosis in the 1960s had a median survival of around 5 years but this has improved with each subsequent decade and is now more than 40 years in many developed countries.1,2 This improvement in outcomes and quality of life has been due to a combination of care delivered by expert cystic fibrosis centres and the implementation of effective new therapies developed through randomised controlled trials.

中文翻译:

重点进行临床试验研究:确保新型囊性纤维化药物发挥其潜能

文章首页在过去的50年中,在改善囊性纤维化患者的预后方面取得了非凡的进步。1960年代出生的患有囊性纤维化的儿童的中位生存期约为5年,但随后的每十年都有所改善,现在在许多发达国家已经超过40年。1,2结局和生活质量的改善归因于专家性囊性纤维化中心提供的护理以及通过随机对照试验开发的有效新疗法的结合。
更新日期:2017-08-26
down
wechat
bug